|[July 07, 2014]
JenaValve Names David J. Drachman Chief Executive Officer
IRVINE, Calif. & MUNICH --(Business Wire)--
JenaValve Technology, Inc., a privately-held, venture-backed developer,
manufacturer and marketer of transcatheter aortic valve implantation
(TAVI) systems for the treatment of aortic valve disease, today
announced that medical device industry veteran David J. Drachman has
been named the Company's new chief executive officer, effective
JenaValve CEO David J. Drachman (Photo: Business Wire)
Mr. Drachman brings nearly 30 years of leadership in the cardiovascular
medical device industry, including the advancement of cardiovascular
devices from concept to commercial success in markets around the world.
From January 2002 to September 2012, Mr. Drachman served as president,
chief executive officer and a member of the board of directors of
AtriCure (NASDAQ: ATRC), a leading atrial fibrillation (AF) medical
device provider. During his tenure, AtriCure became the first and
remains the only company to receive U.S. Food and Drug Administration
approval for the surgical treatment of AF, expanded its product
portfolio from one to six unique platforms and grew from a startup
company to the market leader with sales in more than 30 countries.
"Mr. Drachman is joining JenaValve at a key point in the Company's
evolution," said chairman of the board Raymond W. Cohen. "David is a
recognized leader who is highly competitive and up to the challenge of
positioning JenaValve as a significant player in the TAVI space. The
board and I look forward to working closely with David to achieve those
Prior to AtriCure, Mr. Drachman held key executive positions at Biosense
Webster, today a Johnson & Johnson company, where he led initial
commercialization efforts in the European and U.S. markets. Previously,
Mr. Drachman served as acting CEO, WorldwidePresident & Director of
Impulse Dynamics and held leadership positions at Ventritex and Boston
Mr. Drachman commented, "JenaValve has developed and commercialized a
truly unique TAVI system that has proven advantages for both physicians
and patients. The Company now seeks to translate its innovation into a
broader product platform, complete clinical study work and gain the CE
Mark for our transfemoral pericardial tissue TAVI product, accelerate
commercial growth in Europe and aggressively pursue serving new and
larger geographies, including the United States and China."
Former CEO Helmut J. Straubinger said, "The last 8 years have been the
most exciting period in my professional life. After having built
JenaValve from scratch to a solid, well respected company with excellent
products, it is time now for the next big step for the Company. I have
no doubt that David has the expertise to enlarge JenaValve's
international presence and lead the Company going forward."
About the JenaValve TAVI System
The JenaValve™ is a true second-generation catheter-based aortic valve
implantation system engineered and manufactured to the highest quality
standards. The JenaValve transapical TAVI system is currently being sold
in Europe and other markets around the world for Aortic Stenosis and
Aortic Insufficiency. To date, the JenaValve system is the only TAVI
product that has a CE Mark to treat patients with Aortic Insufficiency.
The Company's transfemoral TAVI system entered into a first-in-man
clinical study at the end of 2013 and is anticipated to be commercially
available for sale in 2015.
JenaValve's unique "3-feeler element" allows the clinician to
accurately position the prosthesis in the anatomically correct
position during implantation thus ensuring to achieve the correct
implantation height and commissural alignment within the patient's
JenaClip™ anchoring and clamping mechanism allows the
prosthesis to be clamped onto the patient's native valve leaflets
enabling the JenaValve to be firmly anchored in the correct anatomical
position and provide active fixation and resistance to migration.
The JenaValve implantation is conducted on the beating heart.
Hemodynamic flow is maintained without cardiac arrest and rapid pacing
is not required during the procedure. The low profile and the open
cell design of the stent prosthesis ensure open flow to the coronaries
after the implantation. The JenaValve is available in three sizes
covering aortic valve annuli from 21mm to 27mm.
JenaValve is retrievable and repositionable thereby
contributing to a successful procedure and confidence of the clinician.
JenaValve Technology, Inc., based in Munich, Germany and Irvine,
California, develops, manufactures and markets transcatheter aortic
valve implantation (TAVI) systems to treat patients suffering from
aortic valve disease. The Company's transapical TAVI system is CE marked
and currently marketed in Europe and other markets worldwide and its new
transfemoral TAVI system is currently undergoing clinical evaluation in
Europe with a view toward achieving CE Mark in 2015. JenaValve is backed
by world-class U.S., European and Asian investors, including Atlas
Venture, Edmond de Rothschild Investment Partners, GIMV, NeoMed
Management, Legend Capital, VI Partners, Sunstone Capital, Omega Funds,
Biovest and Valiance Advisors.
Additional information is available at www.jenavalve.com.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140707005239/en/
[ Back To TMCnet.com's Homepage ]